As per Freedonia, world demand for pharmaceutical packaging products will increase 6.4% pa to US$90 bln in 2017. Because of advanced and diverse drug producing industries, almost 65% of global demand will exist in the developed economies of Canada, Japan, the US and Western Europe. India and China will form the fastest growing markets due to rapidly expanding pharmaceutical manufacturing capabilities and the adoption of more stringent regulations aimed at improving the quality and integrity of domestically produced medicines. Turkey, Mexico and Brazil are among other developing countries that are expected to expand and diversify drug producing industries and register above average gains in pharmaceutical packaging product demand. Over the long term, the US will continue to form the largest national pharmaceutical packaging product market as its advanced drug producing sector commercializes new sophisticated therapies with specialized packaging needs. Demand in Western Europe will remain comparatively high and expand steadily due to the impact of new product introductions and upgraded government standards covering unit dose, high barrier and anti-counterfeit packaging of many types of medicines. Based on broad contingents of proprietary and generic drug producers, Canada and Japan will continue to be large, diverse consumers of pharmaceutical packaging products. However, both countries will see below average growth in demand as drug makers pursue greater packaging efficiencies to offset medication pricing pressures. Global demand for primary pharmaceutical containers will expand 6.6% pa to more than US$57 bln in 2017. Prefillable syringes and parenteral vials will lead growth as new injectable therapies developed through biotechnology and related methods are introduced into the marketplace. Based on uses in the bulk and prescription dose packaging of oral ethical drugs and the large quantity packaging of solid dose oral over-the-counter medicines, plastic bottles will continue to record the largest demand globally among primary pharmaceutical containers, or US$20.6 bln in 2017. Blister packaging will comprise the second largest selling group of these containers based on its adaptability to unit dose and clinical trial dosage formats with expanded label content, high visibility, and built-in track and trace features.